MultifacetedProtDB - Bologna Biocomputing Group

EC number	EC number description
3.6.4.10	Hydrolases; Acting on acid anhydrides; Acting on acid anhydrides to facilitate cellular and subcellular movement; non-chaperonin molecular chaperone ATPase

Structure

PDB	Resolution (Å)	PDB name
2BYH	1.9	3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone
2CCT	2.3	HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL- 2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE
2YE7	2.2	HSP90 inhibitors and drugs from fragment and virtual screening
4YKX	1.8	Heat Shock Protein 90 Bound to CS318
2QF6	3.1	HSP90 complexed with A56322
6GQR	2.05	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCPP
4LWI	1.7	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6
4CWN	1.8	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
2FWY	2.1	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H64
6U9A	1.65	Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 5
3RLQ	1.9	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5- carbonitrile
6GP8	1.75	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex AMPCPP
6F1N	2.09	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
6FCJ	2.49	Estimation of Protein-Ligand Unbinding Kinetics Using Non-Equilibrium Targeted Molecular Dynamics Simulations
4L90	2.001	Crystal structure of Human Hsp90 with RL3
3R4O	2.65	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
6GPH	1.56	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPCP
6FDP		NMR structure of the second TPR domain of the human RPAP3 protein in complex with HSP90 peptide DTSRMEEVD
4O0B	1.93	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
2QG2	1.8	HSP90 complexed with A917985
5LO0	2.3	HSP90 WITH indazole derivative
5XRE	1.497	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor JX1
3QTF	1.5703	Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity
4O04	1.82	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
2CCU	2.7	HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4-METHANESULPHONYL-BENZYL)- PIERAZIN-1-YL)-1H-PYRAZOL-3-YL)-BENZENE-1,3-DIOL
4CWF	2.0	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
2YJW	1.61	Tricyclic series of Hsp90 inhibitors
2XDS	1.97	Structure of HSP90 with small molecule inhibitor bound
4CWS	2.3	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
6GR3	1.88	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPPNP
4JQL	1.72	Synthesis of Benzoquinone-Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid
3QDD	1.79	HSP90A N-terminal domain in complex with BIIB021
1UY6	1.9	Human Hsp90-alpha with 9-Butyl-8-(3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
2YEC	2.1	HSP90 inhibitors and drugs from fragment and virtual screening
4EGK	1.69	Human Hsp90-alpha ATPase domain bound to Radicicol
8AGL	2.2	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with JMC31
6CYH	1.49	Hsp90-alpha N-domain bound to NEACA
2XJG	2.25	Structure of HSP90 with small molecule inhibitor bound
5J6N	1.9	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide
4W7T	1.8	Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990
3R4P	1.7	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
1UYK	2.2	Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-2-fluoro-9H-purin-6-ylamine
7LT0	1.697	Hsp90a N-terminal inhibitor
5LR7	1.86	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR567530
6GR4	1.5	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R
2QFO	1.68	HSP90 complexed with A143571 and A516383
2XJJ	1.9	Structure of HSP90 with small molecule inhibitor bound
5FND	2.0	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
5M4H	2.0	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
4YKT	1.85	Heat Shock Protein 90 Bound to CS307
4EFU	2.0	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid benzyl-methyl-amide
2YE5	1.73	HSP90 inhibitors and drugs from fragment and virtual screening
4L8Z	1.703	Crystal structure of Human Hsp90 with RL1
2WI6	2.18	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
3B26	2.1	Hsp90 alpha N-terminal domain in complex with an inhibitor Ro1127850
4YKR	1.61	Heat Shock Protein 90 Bound to CS302
1OSF	1.75	Human Hsp90 in complex with 17-desmethoxy-17-N,N-Dimethylaminoethylamino-Geldanamycin
7L7J	3.1	Cryo-EM structure of Hsp90:p23 closed-state complex
2YI0	1.6	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
2XJX	1.66	Structure of HSP90 with small molecule inhibitor bound
3FT8	2.0	Structure of HSP90 bound with a noval fragment.
2YEA	1.73	HSP90 inhibitors and drugs from fragment and virtual screening
5LO6	2.4	HSP90 WITH indazole derivative
6B99	1.60238	Hsp90-alpha N-domain bound to NECA
3RLR	1.7	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-2,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
3HZ1	2.3	Crystal structure of Hsp90 with fragments 37-D04 and 42-C03
8AGJ	2.32	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with JMC31
5J8M	1.9	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
4YKU	1.7	Heat Shock Protein 90 Bound to CS311
5ZR3	2.5	Crystal structure of Hsp90-alpha N-terminal domain in complex with 4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3-methylbenzamide
2WI5	2.1	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
7S99	1.52	Room-temperature Human Hsp90a-NTD bound to N6M
6U98	1.5	Hsp90a NTD K58R bound reversibly to sulfonyl fluoride 6
5OD7	2.0	Hsp90 inhibitor desolvation as a rationale to steer on-rates and impact residence time
4EGI	1.79	Hsp90-alpha ATPase domain in complex with 2-Amino-4-ethylthio-6-methyl-1,3,5-triazine
5NYI	1.44	Crystal Structure of Hsp90-alpha N-Domain in complex with Resorcinol derivative
3K98	2.4	HSP90 N-terminal domain in complex with (1R)-2-(5-chloro-2,4-dihydroxybenzoyl)-N-ethylisoindoline-1-carboxamide
2XDX	2.42	Structure of HSP90 with small molecule inhibitor bound
3INX	1.75	HSP90 N-TERMINAL DOMAIN with pochoxime B
2YEG	2.5	HSP90 inhibitors and drugs from fragment and virtual screening
7L7I	3.3	Cryo-EM structure of Hsp90:FKBP51:p23 closed-state complex
1YET	1.9	GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING DOMAIN
6HHR	2.0	Hsp90 in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazole-3-thione
2XDL	1.98	Structure of HSP90 with small molecule inhibitor bound
5LQ9	1.9	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR200323.
6GPY	2.25	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPPNP
6GPP	1.51	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with ADP
2YJX	1.83	Tricyclic series of Hsp90 inhibitors
5J8U	1.75	Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
1UYL	1.4	Structure-Activity Relationships in purine-based inhibitor binding to HSP90 isoforms
2YK9	1.32	Tricyclic series of Hsp90 inhibitors
4AWQ	1.6	Complex of HSP90 ATPase domain with tropane derived inhibitors
5J6M	1.64	Crystal Structure of Hsp90-alpha N-domain L107 mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide
4EFT	2.12	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-Cyclohexyl-2-(6-hydroxy-1H-indazol-3-yl)-propionitrile
4YKZ	1.85	Heat Shock Protein 90 Bound to CS320
3EKR	2.0	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
5J2V	1.59	Crystal Structure of Hsp90-alpha Apo N-domain
2WI1	2.3	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
2YKB	1.93	Tricyclic series of Hsp90 inhibitors
7RY1	3.523	human Hsp90_MC domain structure
4AIF	2.006	AIP TPR domain in complex with human Hsp90 peptide
4BQG	1.9	structure of HSP90 with an inhibitor bound
6CYG	1.50392	Hsp90-alpha N-domain bound to NEOCA
1YC4	1.81	Crystal structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles
1UYD	2.2	Human Hsp90-alpha with 9-Butyl-8-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine
5LS1	1.85	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR166475
4AWO	1.7	Complex of HSP90 ATPase domain with tropane derived inhibitors
2WI2	2.09	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
4O05	1.79	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
6GP4	1.7	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A
3R4N	2.0	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
4YKY	1.78	Heat Shock Protein 90 Bound to CS319
2YI5	2.5	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
4NH8	1.65	Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity
6GQU	1.72	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with cAMP
1UYG	2.0	Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
2YK2	1.74	Tricyclic series of Hsp90 inhibitors
7S9G	1.79	Room-temperature Human Hsp90a-NTD bound to BIIB021
2XK2	1.95	Structure of HSP90 with small molecule inhibitor bound
4L91	1.75	Crystal structure of Human Hsp90 with X29
3T0H	1.2	Structure insights into mechanisms of ATP hydrolysis and the activation of human Hsp90
4FCQ	2.151	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
5LRZ	2.0	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003643501
3MNR	1.9	Crystal Structure of Benzamide SNX-1321 bound to Hsp90
5VYY	1.792	Structure of human Hsp90-alpha bound to resorcinylic inhibitor BnIm
4XIR	1.7	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
8AGI	2.1	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with JMC31
6N8X	1.49484	Hsp90-alpha bound to PU-11-trans
2WI7	2.5	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
3WHA	1.3	Hsp90 alpha N-terminal domain in complex with a tricyclic inhibitor
4L94	1.649	Crystal structure of Human Hsp90 with S46
3O0I	1.47	Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor PU-H54
3B28	1.35	Hsp90 alpha N-terminal domain in complex with an inhibitor CH5015765
4AWP	1.82	Complex of HSP90 ATPase domain with tropane derived inhibitors
2YE2	1.9	HSP90 inhibitors and drugs from fragment and virtual screening
4BQJ	2.0	structure of HSP90 with an inhibitor bound
4LWH	1.7	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5
3HZ5	1.9	Crystal structure of Hsp90 with fragment Z064
3FT5	1.9	Structure of HSP90 bound with a novel fragment
3BMY	1.6	Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90
3K97	1.95	HSP90 N-terminal domain in complex with 4-chloro-6-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
3B24	1.7	Hsp90 alpha N-terminal domain in complex with an aminotriazine fragment molecule
4CWO	2.31	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
3R92	1.5801	Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
3EKO	1.55	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
5J2X	1.22	Crystal Structure of Hsp90-alpha N-domain in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
7RXZ	3.152	human Hsp90_MC domain structure
5J20	1.76	HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide
6LSZ	1.992	HSP 90 in complex with Ganetespib
3OWB	2.05	Crystal Structure of HSP90 with VER-49009
5J27	1.7	HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide
2XDK	1.97	Structure of HSP90 with small molecule inhibitor bound
5J82	2.17	Crystal Structure of Hsp90-alpha N-domain in complex 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-isopropyl-N-methyl-benzenesulfonamide
5LRL	1.33	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003492875
4CGW	3.001	Second TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD
6EL5	1.67	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
5XRD	1.3	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FS7
5XQD	1.6	Crystal structure of Human Hsp90 with FS2
4CWQ	2.0	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
6GQS	1.43	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCP
5LO5	1.44	HSP90 WITH indole derivative
3B27	1.5	Hsp90 alpha N-terminal domain in complex with an inhibitor Ro4919127
5J6L	1.75	Crystal Structure of Hsp90-alpha N-domain in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide
1UYC	2.0	Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-9H-purin-6-ylamine
2YI7	1.4	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
6GR1	2.05	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with AMPCPP
3INW	1.95	HSP90 N-TERMINAL DOMAIN with pochoxime A
4CGQ	2.0	Full length Tah1 bound to HSP90 peptide SRMEEVD
1UY8	1.98	Human Hsp90-alpha with 9-Butyl-8-(3-trimethoxy-benzyl)-9H-purin-6ylamine
6ELP	1.85	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
5J64	1.38	Crystal Structure of Hsp90-alpha N-domain in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one
2VCI	2.0	4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
4YKW	1.85	Heat Shock Protein 90 Bound to CS312
4FCR	1.698	Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
3R91	1.579	Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
2BUG		Solution structure of the TPR domain from Protein phosphatase 5 in complex with Hsp90 derived peptide
1YES	2.2	HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, OPEN CONFORMATION
7S9H	1.45	Cryogenic Human Hsp90a-NTD bound to EC144
1UYE	2.0	Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-9-pent-4-ylnyl-9H-purin-6-ylamine
6LT8	1.593	HSP90 in complex with KW-2478
5M4E	1.9	Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
3VHD	1.52	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor, CH5164840
2YED	2.1	HSP90 inhibitors and drugs from fragment and virtual screening
2H55	2.0	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-DZ8
4U93	1.55	Crystal Structure of Hsp90-alpha N-domain Bound to the Inhibitor NVP-HSP990
6GR5	1.34	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112R in complex with ADP
3R4M	1.7	Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
2QG0	1.85	HSP90 complexed with A943037
1YC3	2.12	Crystal Structure of human HSP90alpha complexed with dihydroxyphenylpyrazoles
3BM9	1.6	Discovery of Benzisoxazoles as Potent Inhibitors of Chaperone Hsp90
2JJC	1.95	Hsp90 alpha ATPase domain with bound small molecule fragment
1UY7	1.9	Human Hsp90-alpha with 9-Butyl-8-(4-methoxy-benzyl)-9H-purin-6-ylamine
3OW6	1.8	Crystal Structure of HSP90 with N-Aryl-benzimidazolone I
3B25	1.75	Hsp90 alpha N-terminal domain in complex with an inhibitor CH4675194
2UWD	1.9	Inhibition of the HSP90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole, isoxazole amide analogs
2WI4	2.4	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
3RLP	1.7	Co-crystal structure of the HSP90 ATP binding domain in complex with 4-(2,4-dichloro-5-methoxyphenyl)-6-methylpyrimidin-2-amine
2YE8	2.3	HSP90 inhibitors and drugs from fragment and virtual screening
6LTI	1.588	HSP90 in complex with NVP-AUY922
4L93	1.845	Crystal structure of Human Hsp90 with S36
2BSM	2.05	Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
3WQ9	1.8	Crystal structure of Hsp90-alpha N-terminal domain in complex with 2-(4-Hydroxy-cyclohexylamino)-4-[5-(4-phenyl-imidazol-1-yl)-isoquinolin-1-yl]-benzamide
5CF0	1.8	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6
7DMC	2.34	Dipyridamole binds to the N-terminal domain of human Hsp90A
3HYZ	2.3	Crystal structure of Hsp90 with fragment 42-C03
2YEE	2.3	HSP90 inhibitors and drugs from fragment and virtual screening
4CWP	1.95	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
4O09	1.96	Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington s disease
6GPF	1.55	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with AMPPNP
5LNZ	1.54	HSP90 WITH indazole derivative
6EYB	1.9	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
4EGH	1.6	Hsp90-alpha ATPase domain in complex with (4-Hydroxyphenyl)morpholin-4-yl methanone
3T0Z	2.192	Hsp90 N-terminal domain bound to ATP
7S9I	1.75	Room-temperature Human Hsp90a-NTD bound to EC144
6KSQ	2.202	Middle Domain of Human HSP90 Alpha
5OCI	1.62	Human Heat Shock Protein 90 bound to 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide
6U99	1.6	Hsp90a NTD covalently bound to sulfonyl fluoride probe 1 at K58
4YKQ	1.91	Heat Shock Protein 90 Bound to CS301
3T2S	1.501	HSP90 N-terminal domain bound to AGS
3T1K	1.5	HSP90 N-terminal domain bound to ANP
2YE4	2.3	HSP90 inhibitors and drugs from fragment and virtual screening
2YEB	2.4	HSP90 inhibitors and drugs from fragment and virtual screening
4O07	1.86	Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease
4XIQ	1.84	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
4EEH	1.6	Hsp90 Alpha N-terminal Domain in Complex with an Inhibitor 3-(4-Hydroxy-phenyl)-1H-indazol-6-ol
7S90	1.79	Cryogenic Human Hsp90a-NTD bound to adenine
5LO1	2.7	HSP90 WITH indazole derivative
3Q6M	3.0	Crystal Structure of Human MC-HSP90 in C2221 Space Group
6OLX	1.43761	Hsp90-alpha S52A bound to PU-11-trans
2YKE	1.43	Tricyclic series of Hsp90 inhibitors
2XHX	2.801	Structure of HSP90 with small molecule inhibitor bound
2CCS	1.79	HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-3-YL)- BENZENE-1,2-DIOL
6EYA	2.1	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
7S98	1.9	Cryogenic Human Hsp90a-NTD bound to N6M
5XRB	1.65	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ5
6GPT	2.0	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with AMPCP
5J80	1.17	Crystal Structure of Apo Hsp90-alpha N-domain L107A mutant
2YE3	1.95	HSP90 inhibitors and drugs from fragment and virtual screening
6LTK	2.141	HSP90 in complex with SNX-2112
2BYI	1.6	3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as Inhibitors of the Hsp90 Molecular Chaperone
4LWE	1.5	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ2
3HYY	1.9	Crystal structure of Hsp90 with fragment 37-D04
2FWZ	2.1	Structure of human Hsp90-alpha bound to the potent water soluble inhibitor PU-H71
3T10	1.24	HSP90 N-terminal domain bound to ACP
6TN4	1.274	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6GPO	1.48	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) variant K112A in complex with cAMP
3TUH	1.8	Crystal Structure of the N-terminal domain of an HSP90 in the presence of an the inhibitor ganetespib
5XQE	1.699	Crystal structure of Human Hsp90 with FS3
5XR9	1.501	Crystal structure of Human Hsp90 with FS6
2BZ5	1.9	Structure-based Discovery of a New Class of Hsp90 Inhibitors
7S95	1.71	Room-temperature Human Hsp90a-NTD bound to adenine
6LR9	2.196	HSP90 in complex with Debio0932
6EY8	2.16	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
2YKJ	1.46	Tricyclic series of Hsp90 inhibitors
1BYQ	1.5	HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG
4CWR	2.0	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
1YER	1.65	HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, CLOSED CONFORMATION
4HY6	1.649	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ1
2YEI	2.2	HSP90 inhibitors and drugs from fragment and virtual screening
4CWT	1.9	Human HSP90 alpha N-terminal domain in complex with an Aminotriazoloquinazoline inhibitor
1UYH	2.2	Human Hsp90-alpha with 9-Butyl-8-(2,5-dimethoxy-benzyl)-2-fluoro-9H-purin-6-ylamine
2C2L	3.3	Crystal structure of the CHIP U-box E3 ubiquitin ligase
4XIP	1.7	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
6EY9	2.0	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
5NYH	1.65	Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative
5XR5	1.6	Crystal structure of Human Hsp90 with FS4
5J86	1.87	Crystal Structure of Hsp90-alpha N-domain in complex with 2,4-Dihydroxy-N-methyl-5-(5-oxo-4-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-N-thiophen-2-ylmethyl-benzamide
4FCP	2.0	Targetting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo [2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization
5J9X	1.8	HSP90 in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide
2WI3	1.9	Orally Active 2-Amino Thienopyrimidine Inhibitors of the Hsp90 Chaperone
5LR1	1.44	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003498614A.
3D0B	1.74	Crystal Structure of Benzamide Tetrahydro-4H-carbazol-4-one bound to Hsp90
1UY9	2.0	Human Hsp90-alpha with 8-Benzo[1,3]dioxol-,5-ylmethyl-9-butyl-9H-purin-6-ylamine
3K99	2.1	HSP90 N-terminal domain in complex with 4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)benzene-1,3-diol
5FNF	2.1	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
7S9F	2.3	Cryogenic Human Hsp90a-NTD bound to BIIB021
7KW7	3.57	Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR
2YEF	1.55	HSP90 inhibitors and drugs from fragment and virtual screening
6CEO	1.896	Structure of Hsp90 NTD with a GRP94-selective resorcinylic inhibitor.
7KRJ	2.56	The GR-Maturation Complex: Glucocorticoid Receptor in complex with Hsp90 and co-chaperone p23
4LWF	1.75	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ3
5LNY	1.88	HSP90 WITH indazole derivative
2XHR	2.2	Structure of HSP90 with small molecule inhibitor bound
6ELO	1.8	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
2YEJ	2.2	HSP90 inhibitors and drugs from fragment and virtual screening
5T21	2.1	CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR148019.
4LWG	1.599	Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ4
2YKC	1.67	Tricyclic series of Hsp90 inhibitors
2YE9	2.2	HSP90 inhibitors and drugs from fragment and virtual screening
5GGZ	2.015	Crystal structure of novel inhibitor bound with Hsp90
1UYF	2.0	Human Hsp90-alpha with 8-(2-chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine
6U9B	1.75	Hsp90a NTD covalently bound to sulfonyl fluoride 5 at K58
6EI5	2.2	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
7LSZ	1.7	Hsp90a N-terminal inhibitor
3HHU	1.59	Human heat-shock protein 90 (HSP90) in complex with {4-[3-(2,4-dihydroxy-5-isopropyl-phenyl)-5-thioxo- 1,5-dihydro-[1,2,4]triazol-4-yl]-benzyl}-carbamic acid ethyl ester {ZK 2819}
6GPW	1.6	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD)
7RY0	2.2	human Hsp90_MC domain structure
2K5B		Human CDC37-HSP90 docking model based on NMR
4XIT	1.86	Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors
4B7P	1.7	Structure of HSP90 with NMS-E973 inhibitor bound
2YE6	2.56	HSP90 inhibitors and drugs from fragment and virtual screening
2XHT	2.27	Structure of HSP90 with small molecule inhibitor bound
6TN5	1.165	Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
4NH7	2.0	Correlation between chemotype-dependent binding conformations of HSP90 alpha/beta and isoform selectivity
4CGU	2.11	Full length Tah1 bound to yeast PIH1 and HSP90 peptide SRMEEVD
3VHA	1.39	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor
6ELN	1.6	Estimation of relative drug-target residence times by random acceleration molecular dynamics simulation
3HEK	1.95	HSP90 N-terminal domain in complex with 1-{4-[(2R)-1-(5-chloro-2,4-dihydroxybenzoyl)pyrrolidin-2-yl]benzyl}-3,3-difluoropyrrolidinium
5FNC	2.2	Dynamic Undocking and the Quasi-Bound State as tools for Drug Design
2YKI	1.67	Tricyclic series of Hsp90 inhibitors
7UR3	1.6	Hsp90 alpha inhibitor
7S8Z	1.64	Room-temperature apo Human Hsp90a-NTD
6B9A	1.65381	Hsp90-alpha N-domain bound to NPCA
3OWD	1.63	Crystal Structure of HSP90 with N-Aryl-benzimidazolone II
2YEH	2.1	HSP90 inhibitors and drugs from fragment and virtual screening
2XDU	1.74	Structure of HSP90 with small molecule inhibitor bound
1YC1	1.7	Crystal Structures of human HSP90alpha complexed with dihydroxyphenylpyrazoles
5ODX	1.82	Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative
6GQ6	2.25	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with ADP
6GPR	2.35	Structure of human Heat shock protein 90-alpha N-terminal domain (Hsp90-NTD) in complex with cAMP
2XAB	1.9	Structure of HSP90 with an inhibitor bound
4CGV	2.54	First TPR of Spaghetti (RPAP3) bound to HSP90 peptide SRMEEVD
7S8Y	1.59	Cryogenic apo Human Hsp90a-NTD
3Q6N	3.05	Crystal Structure of Human MC-HSP90 in P21 space group
2YI6	1.8	Structural characterization of 5-Aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
4R3M	1.8	Crystal structure of Human Hsp90 with JR9
2BT0	1.9	Novel, potent small molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
3RKZ	1.5693	Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor capable of significantly decreasing tumor volume in a mouse xenograft model.
2VCJ	2.5	4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
1UYI	2.2	Human Hsp90-alpha with 8-(2,5-dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine
3VHC	1.41	Hsp90 alpha N-terminal domain in complex with a macrocyclic inhibitor

GO term

GO ontology	GO term	GO description
Biological Process	GO:0002218	activation of innate immune response
Biological Process	GO:0048675	axon extension
Biological Process	GO:0010659	cardiac muscle cell apoptotic process
Biological Process	GO:0034605	cellular response to heat
Biological Process	GO:0098586	cellular response to virus
Biological Process	GO:0021955	central nervous system neuron axonogenesis
Biological Process	GO:0061684	chaperone-mediated autophagy
Biological Process	GO:0051131	chaperone-mediated protein complex assembly
Biological Process	GO:0030010	establishment of cell polarity
Biological Process	GO:0006839	mitochondrial transport
Biological Process	GO:0001764	neuron migration
Biological Process	GO:0060452	positive regulation of cardiac muscle contraction
Biological Process	GO:0045793	positive regulation of cell size
Biological Process	GO:0002230	positive regulation of defense response to virus by host
Biological Process	GO:0032728	positive regulation of interferon-beta production
Biological Process	GO:0010592	positive regulation of lamellipodium assembly
Biological Process	GO:0045429	positive regulation of nitric oxide biosynthetic process
Biological Process	GO:0033138	positive regulation of peptidyl-serine phosphorylation
Biological Process	GO:0045732	positive regulation of protein catabolic process
Biological Process	GO:0042307	positive regulation of protein import into nucleus
Biological Process	GO:0051897	positive regulation of protein kinase B signaling
Biological Process	GO:0001934	positive regulation of protein phosphorylation
Biological Process	GO:0032273	positive regulation of protein polymerization
Biological Process	GO:1902949	positive regulation of tau-protein kinase activity
Biological Process	GO:0051973	positive regulation of telomerase activity
Biological Process	GO:0006457	protein folding
Biological Process	GO:0045040	protein insertion into mitochondrial outer membrane
Biological Process	GO:0042026	protein refolding
Biological Process	GO:0050821	protein stabilization
Biological Process	GO:0043335	protein unfolding
Biological Process	GO:0042981	regulation of apoptotic process
Biological Process	GO:0099072	regulation of postsynaptic membrane neurotransmitter receptor levels
Biological Process	GO:0032880	regulation of protein localization
Biological Process	GO:0031396	regulation of protein ubiquitination
Biological Process	GO:0043254	regulation of protein-containing complex assembly
Biological Process	GO:0046677	response to antibiotic
Biological Process	GO:0042220	response to cocaine
Biological Process	GO:0009409	response to cold
Biological Process	GO:0043627	response to estrogen
Biological Process	GO:0009408	response to heat
Biological Process	GO:0009651	response to salt stress
Biological Process	GO:0006986	response to unfolded protein
Biological Process	GO:0009410	response to xenobiotic stimulus
Biological Process	GO:0003009	skeletal muscle contraction
Biological Process	GO:1905323	telomerase holoenzyme complex assembly
Biological Process	GO:0007004	telomere maintenance via telomerase
Molecular Function	GO:0005524	ATP binding
Molecular Function	GO:0016887	ATP hydrolysis activity
Molecular Function	GO:0140662	ATP-dependent protein folding chaperone
Molecular Function	GO:0002135	CTP binding
Molecular Function	GO:0070182	DNA polymerase binding
Molecular Function	GO:0005525	GTP binding
Molecular Function	GO:0051020	GTPase binding
Molecular Function	GO:0023026	MHC class II protein complex binding
Molecular Function	GO:0003723	RNA binding
Molecular Function	GO:0051022	Rho GDP-dissociation inhibitor binding
Molecular Function	GO:0030911	TPR domain binding
Molecular Function	GO:0002134	UTP binding
Molecular Function	GO:0032564	dATP binding
Molecular Function	GO:0097718	disordered domain specific binding
Molecular Function	GO:0042826	histone deacetylase binding
Molecular Function	GO:0042802	identical protein binding
Molecular Function	GO:0003729	mRNA binding
Molecular Function	GO:0030235	nitric-oxide synthase regulator activity
Molecular Function	GO:0042803	protein homodimerization activity
Molecular Function	GO:0019903	protein phosphatase binding
Molecular Function	GO:1990782	protein tyrosine kinase binding
Molecular Function	GO:0097110	scaffold protein binding
Molecular Function	GO:0017098	sulfonylurea receptor binding
Molecular Function	GO:0048156	tau protein binding
Molecular Function	GO:0044325	transmembrane transporter binding
Molecular Function	GO:0031625	ubiquitin protein ligase binding
Molecular Function	GO:0051082	unfolded protein binding
Cellular Component	GO:0016324	apical plasma membrane
Cellular Component	GO:0044295	axonal growth cone
Cellular Component	GO:0016323	basolateral plasma membrane
Cellular Component	GO:0031526	brush border membrane
Cellular Component	GO:0009986	cell surface
Cellular Component	GO:0062023	collagen-containing extracellular matrix
Cellular Component	GO:0005737	cytoplasm
Cellular Component	GO:0005829	cytosol
Cellular Component	GO:0044294	dendritic growth cone
Cellular Component	GO:0071682	endocytic vesicle lumen
Cellular Component	GO:0070062	extracellular exosome
Cellular Component	GO:0005576	extracellular region
Cellular Component	GO:1904813	ficolin-1-rich granule lumen
Cellular Component	GO:0043202	lysosomal lumen
Cellular Component	GO:0042470	melanosome
Cellular Component	GO:0016020	membrane
Cellular Component	GO:0005739	mitochondrion
Cellular Component	GO:0043209	myelin sheath
Cellular Component	GO:0043025	neuronal cell body
Cellular Component	GO:0005654	nucleoplasm
Cellular Component	GO:0005634	nucleus
Cellular Component	GO:0048471	perinuclear region of cytoplasm
Cellular Component	GO:0005886	plasma membrane
Cellular Component	GO:0032991	protein-containing complex
Cellular Component	GO:0034774	secretory granule lumen
Cellular Component	GO:0097226	sperm mitochondrial sheath
Cellular Component	GO:0097524	sperm plasma membrane

InterPro / Pfam

InterPro	InterPro name
IPR001404	Heat shock protein Hsp90 family
IPR003594	Histidine kinase/HSP90-like ATPase
IPR019805	Heat shock protein Hsp90, conserved site
IPR020568	Ribosomal protein S5 domain 2-type fold
IPR020575	Heat shock protein Hsp90, N-terminal
IPR036890	Histidine kinase/HSP90-like ATPase superfamily
IPR037196	HSP90, C-terminal domain

Pfam	Pfam name
PF00183	Hsp90 protein
PF02518	Histidine kinase-, DNA gyrase B-, and HSP90-like ATPase

Reactome

Reactome	Reactome Name	Node type	Reactome Root	Reactome Root Name
R-HSA-1227986	Signaling by ERBB2	Internal node	R-HSA-162582	Signal Transduction
R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	Leaf	R-HSA-1643685	Disease
R-HSA-1474151	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	Leaf	R-HSA-1430728	Metabolism
R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	Internal node	R-HSA-168256	Immune System
R-HSA-192905	vRNP Assembly	Leaf	R-HSA-1643685	Disease
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	Leaf	R-HSA-168256	Immune System
R-HSA-203615	eNOS activation	Leaf	R-HSA-1430728	Metabolism
R-HSA-2565942	Regulation of PLK1 Activity at G2/M Transition	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-3000484	Scavenging by Class F Receptors	Leaf	R-HSA-5653656	Vesicle-mediated transport
R-HSA-3371497	HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-3371511	HSF1 activation	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-3371568	Attenuation phase	Leaf	R-HSA-8953897	Cellular responses to stimuli
R-HSA-3371571	HSF1-dependent transactivation	Internal node	R-HSA-8953897	Cellular responses to stimuli
R-HSA-380259	Loss of Nlp from mitotic centrosomes	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-380270	Recruitment of mitotic centrosome proteins and complexes	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-380284	Loss of proteins required for interphase microtubule organization from the centrosome	Internal node	R-HSA-1640170	Cell Cycle
R-HSA-380320	Recruitment of NuMA to mitotic centrosomes	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-399954	Sema3A PAK dependent Axon repulsion	Leaf	R-HSA-1266738	Developmental Biology
R-HSA-4420097	VEGFA-VEGFR2 Pathway	Internal node	R-HSA-162582	Signal Transduction
R-HSA-5218920	VEGFR2 mediated vascular permeability	Leaf	R-HSA-162582	Signal Transduction
R-HSA-5336415	Uptake and function of diphtheria toxin	Leaf	R-HSA-1643685	Disease
R-HSA-5601884	PIWI-interacting RNA (piRNA) biogenesis	Leaf	R-HSA-74160	Gene expression (Transcription)
R-HSA-5620912	Anchoring of the basal body to the plasma membrane	Leaf	R-HSA-1852241	Organelle biogenesis and maintenance
R-HSA-5637810	Constitutive Signaling by EGFRvIII	Leaf	R-HSA-1643685	Disease
R-HSA-5675482	Regulation of necroptotic cell death	Internal node	R-HSA-5357801	Programmed Cell Death
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	Leaf	R-HSA-168256	Immune System
R-HSA-6798695	Neutrophil degranulation	Leaf	R-HSA-168256	Immune System
R-HSA-8852276	The role of GTSE1 in G2/M progression after G2 checkpoint	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-8854518	AURKA Activation by TPX2	Leaf	R-HSA-1640170	Cell Cycle
R-HSA-8863795	Downregulation of ERBB2 signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-8939211	ESR-mediated signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-9009391	Extra-nuclear estrogen signaling	Internal node	R-HSA-162582	Signal Transduction
R-HSA-9013418	RHOBTB2 GTPase cycle	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9018519	Estrogen-dependent gene expression	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9613829	Chaperone Mediated Autophagy	Leaf	R-HSA-9612973	Autophagy
R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	Leaf	R-HSA-1643685	Disease
R-HSA-9646399	Aggrephagy	Leaf	R-HSA-9612973	Autophagy
R-HSA-9652282	Drug-mediated inhibition of ERBB2 signaling	Leaf	R-HSA-162582	Signal Transduction
R-HSA-9664565	Signaling by ERBB2 KD Mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9665233	Resistance of ERBB2 KD mutants to trastuzumab	Leaf	R-HSA-1643685	Disease
R-HSA-9665244	Resistance of ERBB2 KD mutants to sapitinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665245	Resistance of ERBB2 KD mutants to tesevatinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665246	Resistance of ERBB2 KD mutants to neratinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665247	Resistance of ERBB2 KD mutants to osimertinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665249	Resistance of ERBB2 KD mutants to afatinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665250	Resistance of ERBB2 KD mutants to AEE788	Leaf	R-HSA-1643685	Disease
R-HSA-9665251	Resistance of ERBB2 KD mutants to lapatinib	Leaf	R-HSA-1643685	Disease
R-HSA-9665348	Signaling by ERBB2 ECD mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9665737	Drug resistance in ERBB2 TMD/JMD mutants	Leaf	R-HSA-1643685	Disease
R-HSA-9679191	Potential therapeutics for SARS	Leaf	R-HSA-1643685	Disease
R-HSA-9705671	SARS-CoV-2 activates/modulates innate and adaptive immune responses	Leaf	R-HSA-1643685	Disease

Subcellular location

Location	ECO term	Pubmed
Cell membrane	ECO:0000269	PubMed:11276205
Cytoplasm	ECO:0000250
Melanosome	ECO:0000269	PubMed:17081065
Mitochondrion	ECO:0000269	PubMed:25609812
Nucleus	ECO:0000250

Interactor | Variant | Drug

Phenotype

Tissue and cell type

Tissue	Cell type	Expression level	Reliability
adrenal gland	glandular cells	Low	Approved
appendix	glandular cells	Low	Approved
breast	glandular cells	Low	Approved
bronchus	ciliated cells (cell body)	Medium	Approved
cerebellum	Purkinje cells	Low	Approved
cerebral cortex	neuronal cells	Low	Approved
cervix	glandular cells	Low	Approved
colon	glandular cells	Low	Approved
duodenum	glandular cells	Medium	Approved
endometrium 1	glandular cells	Low	Approved
epididymis	glandular cells	Medium	Approved
fallopian tube	ciliated cells (cell body)	High	Approved
gallbladder	glandular cells	Medium	Approved
nasopharynx	ciliated cells (cell body)	High	Approved
placenta	trophoblastic cells	Low	Approved
rectum	glandular cells	Low	Approved
testis	cells in seminiferous ducts	High	Approved
urinary bladder	urothelial cells	Low	Approved

Summary of P07900

Gene: HSP90AA1, HSP90A, HSPC1, HSPCA
Protein: Heat shock protein HSP 90-alpha

Structure

GO term

InterPro / Pfam

Reactome

Subcellular location

Interactor | Variant | Drug

Phenotype

Tissue and cell type

Disease

Summary of P07900

Gene: HSP90AA1, HSP90A, HSPC1, HSPCA Protein: Heat shock protein HSP 90-alpha

Structure

GO term

InterPro / Pfam

Reactome

Subcellular location

Interactor | Variant | Drug

Phenotype

Tissue and cell type

Disease

Gene: HSP90AA1, HSP90A, HSPC1, HSPCA
Protein: Heat shock protein HSP 90-alpha